Of note, treatments with a high dose of APS elevated the IFN-γ/IL-4 ratio (Figure 3(c)) and had promotive effects on IL-17A expression by Th17 cells (Figure 3(d)). This evidence concerns the gene IL17A and autoimmune polyendocrinopathy.